OncoCyte Enterprise Value Over E B I T D A from 2010 to 2024
| OCX Stock | USD 2.44 0.09 3.56% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter (0.54) | Current Value (0.57) | Quarterly Volatility 6.88842331 |
Check OncoCyte Corp financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among OncoCyte Corp's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 49.4 K or Selling General Administrative of 11.2 M, as well as many indicators such as Price To Sales Ratio of 12.09, Dividend Yield of 0.0015 or PTB Ratio of 0.71. OncoCyte financial statements analysis is a perfect complement when working with OncoCyte Corp Valuation or Volatility modules.
OncoCyte | Enterprise Value Over E B I T D A |
Latest OncoCyte Corp's Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of OncoCyte Corp over the last few years. It is OncoCyte Corp's Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in OncoCyte Corp's overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
OncoCyte Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | (9.19) | |
| Coefficient Of Variation | (74.97) | |
| Mean Deviation | 6.33 | |
| Median | (7.41) | |
| Standard Deviation | 6.89 | |
| Sample Variance | 47.45 | |
| Range | 16.6474 | |
| R-Value | 0.94 | |
| Mean Square Error | 5.99 | |
| R-Squared | 0.88 | |
| Slope | 1.45 | |
| Total Sum of Squares | 664.31 |
OncoCyte Enterprise Value Over E B I T D A History
About OncoCyte Corp Financial Statements
OncoCyte Corp investors use historical fundamental indicators, such as OncoCyte Corp's Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in OncoCyte Corp. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | (0.54) | (0.57) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for OncoCyte Stock Analysis
When running OncoCyte Corp's price analysis, check to measure OncoCyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoCyte Corp is operating at the current time. Most of OncoCyte Corp's value examination focuses on studying past and present price action to predict the probability of OncoCyte Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoCyte Corp's price. Additionally, you may evaluate how the addition of OncoCyte Corp to your portfolios can decrease your overall portfolio volatility.